CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ 43,377	$ (421,205)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	274,797	290,419
Goodwill impairment	13,078	511,866
Equity-based compensation	10,614	17,284
Change in fair value of warrant liability	(1,800)	(31,886)
Reduction in the carrying amount of operating lease right-of-use assets	24,902	26,309
Reduction in the carrying amount of finance lease right-of-use assets	7,927	3,821
Deferred income tax expense (benefit)	18,664	(37,033)
Change in fair value of interest rate swaps, net of reclassification adjustment	(367)	(1,394)
Amortization of deferred financing costs	4,247	3,926
Loss on extinguishment of debt	2,273	0
Payment of contingent consideration from an acquisition	(1,850)	0
Other	569	350
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(12,305)	(10,043)
Inventory	(21,474)	12,769
Prepaid and other assets	23,656	10,956
Operating lease obligations	(25,212)	(26,959)
Operating liabilities	30,328	(23,780)
Net cash provided by operating activities	391,424	325,400
Cash flows from investing activities:
Purchases of equipment and other fixed assets	(228,719)	(248,816)
Proceeds from the sale of assets	5,316	0
Payments for business acquisitions, net of cash acquired	0	(17,917)
Payments for cost method investments	0	(128)
Net cash used in investing activities	(223,403)	(266,861)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	253,477	50,000
Repayments on long-term debt and lines of credit	(373,477)	(75,000)
Repayments of finance lease obligations	(8,261)	(4,558)
Payments for shares purchased under share repurchase program	0	(9,224)
Proceeds from the exercise of stock options	742	538
Proceeds received in connection with employee stock purchase plan	999	2,031
Payments relating to the Tax Receivable Agreement	(1,432)	(3,202)
Payments of debt financing costs	(6,429)	0
Distributions to noncontrolling interest	(3,500)	(2,500)
Payments for tax withholdings from restricted stock vesting and stock option exercises	(1,794)	(5,253)
Payments of contingent consideration and deferred purchase price from acquisitions	(5,298)	(1,500)
Net cash used in financing activities	(144,973)	(48,668)
Net increase in cash	23,048	9,871
Cash at beginning of period	77,132	46,272
Cash at end of period	100,180	56,143
Supplemental disclosures:
Cash paid for interest	112,519	113,083
Cash paid for income taxes, net of refunds	13,015	5,727
Noncash investing and financing activities:
Unpaid equipment and other fixed asset purchases at end of period	46,720	32,481
Assets subject to operating lease obligations	24,604	8,179
Operating lease obligations	(24,604)	(8,179)
Write-off of assets subject to operating lease obligations	(3,631)	0
Write-off of operating lease obligations	3,631	0
Assets subject to finance lease obligations	15,665	19,726
Finance lease obligations	(15,665)	(19,726)
Deferred purchase price in connection with acquisitions	$ 0	$ 50